Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.

Bamber, Luke; Muston, Dominic; McLeod, Euan; Guillermin, Anne; Lowin, Julia; Patel, Raj

Bamber, Luke; Muston, Dominic; McLeod, Euan; Guillermin, Anne; Lowin, Julia; Patel, Raj.

Afiliação

Bamber L; Bayer Pharma AG, Wuppertal, Germany.
Muston D; Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ USA.
McLeod E; IMS Health, London, UK.
Guillermin A; IMS Health, London, UK.
Lowin J; IMS Health, London, UK.
Patel R; Department of Haematological Medicine, King's College Hospital, London, UK.

Thromb J ; 13: 20, 2015.

Article em En | MEDLINE | ID: mdl-26074735

Palavras-chave

Cost-effectiveness; Rivaroxaban; Venous thromboembolism treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Thromb J Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google